Disease · MONDO_0015277
Comparisons in its trials30
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 30
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Vandetanib 300 mg vs Placebo: Biochemical Response Carcinoembryonic Antigen (CEA) | 119 of 231 | 2 of 100 | 331 | NCT00410761 | Trial comparisons |
| Vandetanib 300 mg vs Placebo: Biochemical Response Calcitonin (CTN) | 160 of 231 | 3 of 100 | 331 | NCT00410761 | Trial comparisons |
| Vandetanib 300 mg vs Placebo: Disease Control Rate (DCR) | 200 of 231 | 71 of 100 | 331 | NCT00410761 | Trial comparisons |
| Vandetanib 300 mg vs Placebo: Objective Response Rate (ORR) | 104 of 231 | 13 of 100 | 331 | NCT00410761 | Trial comparisons |
| XL184 (Cabozantinib) vs Placebo: serious adverse events | 90 of 214 | 25 of 109 | 323 | NCT00704730 | Trial comparisons |
| Selpercatinib - Treatment A (TRT A) vs Cabozantinib or Vandetanib - Treatment B (TRT B): deaths from any cause | 8 of 193 | 10 of 97 | 290 | NCT04211337 | Trial comparisons |
| Selpercatinib - Treatment A (TRT A) vs Cabozantinib or Vandetanib - Treatment B (TRT B): serious adverse events | 43 of 193 | 27 of 97 | 290 | NCT04211337 | Trial comparisons |
| Cabozantinib (XL184) 60 mg vs Cabozantinib (XL184) 140 mg: deaths from any cause | 59 of 123 | 51 of 124 | 247 | NCT01896479 | Trial comparisons |
| Cabozantinib (XL184) 60 mg vs Cabozantinib (XL184) 140 mg: serious adverse events | 55 of 123 | 62 of 124 | 247 | NCT01896479 | Trial comparisons |
| Vandetanib 300mg vs Vandetanib 300mg + Outreach Program: serious adverse events | 30 of 103 | 27 of 102 | 205 | NCT01298323 | Trial comparisons |
| DTC Cohort vs MTC Cohort: deaths from any cause | 44 of 58 | 37 of 59 | 117 | NCT00784303 | Trial comparisons |
| DTC Cohort vs MTC Cohort: serious adverse events | 32 of 58 | 42 of 59 | 117 | NCT00784303 | Trial comparisons |
Sunitinib Malate-Radioactive Iodine Refractory Subgroup vs Sunitinib Malate-Metastatic Medullary Subgroup: Objective Response Rate, Assessed Using the Response Evaluation Criteria in Solid Tumors (RECIST) | 9 of 38 | 7 of 25 | 63 | NCT00381641 | Trial comparisons |
Sunitinib Malate-Radioactive Iodine Refractory Subgroup vs Sunitinib Malate-Metastatic Medullary Subgroup: Incidence of Toxicity, Graded According to the Common Terminology Criteria for Adverse Events Version 3.0 | 38 of 38 | 24 of 25 | 63 | NCT00381641 | Trial comparisons |
| Sunitinib Malate-Radioactive Iodine Refractory Subgroup vs Sunitinib Malate-Metastatic Medullary Subgroup: deaths from any cause | 21 of 38 | 5 of 25 | 63 | NCT00381641 | Trial comparisons |
| Sunitinib Malate-Radioactive Iodine Refractory Subgroup vs Sunitinib Malate-Metastatic Medullary Subgroup: serious adverse events | 17 of 38 | 12 of 25 | 63 | NCT00381641 | Trial comparisons |
| Phase 1 vs Phase 2 A: Number of Participants With Adverse Events | 21 of 21 | 0 of 1 | 22 | NCT00923247 | Trial comparisons |
| Phase 1 vs Phase 2 A: deaths from any cause | 0 of 21 | 0 of 1 | 22 | NCT00923247 | Trial comparisons |
| Phase 1 vs Phase 2 A: serious adverse events | 4 of 21 | 1 of 1 | 22 | NCT00923247 | Trial comparisons |
| Arm A (Hereditary MTC) vs Arm B (Sporadic MTC): Patient With Decreased Carcinoembryonic Antigen (CEA) Levels | 4 of 5 | 8 of 15 | 20 | NCT00390325 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015277/comparisons